Literature DB >> 19110021

Human dendritic cell maturation and activation by a heat-killed recombinant yeast (Saccharomyces cerevisiae) vector encoding carcinoembryonic antigen.

Cinzia Remondo1, Vittore Cereda, Sven Mostböck, Helen Sabzevari, Alex Franzusoff, Jeffrey Schlom, Kwong-Y Tsang.   

Abstract

Tumor-associated antigens are weakly immunogenic. Human carcinoembryonic antigen (CEA) is overexpressed on a wide range of human carcinomas and represents an attractive target for cancer immunotherapy. This study analyzes the ability of a Saccharomyces cerevisiae vector containing the transgene encoding CEA (yeast-CEA) to activate human dendritic cells (DCs) and stimulate CEA-specific T-cell responses. We demonstrate for the first time that treatment with yeast-CEA can activate human DCs, resulting in increases in surface expression of CD80, CD83, CD54, CD58, and MHC class II, and increased production by DCs of IL-12p70, TNF-alpha, IFN-gamma, IL-8, IL-2, IL-13, IL-10, and IL-1beta. We also show that human DCs treated with yeast-CEA can activate CEA-specific T-cell lines and can act as antigen-presenting cells (APCs) to generate CEA-specific T-cell lines capable of lysing CEA(+) human tumor cells. Gene expression profiles of human DCs treated with yeast-CEA show increased expression of numerous genes involved in the production of chemokines and cytokines and their receptors, and genes related to antigen uptake, antigen presentation, and signal transduction.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19110021      PMCID: PMC3518400          DOI: 10.1016/j.vaccine.2008.12.002

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  46 in total

1.  Toll-dependent selection of microbial antigens for presentation by dendritic cells.

Authors:  J Magarian Blander; Ruslan Medzhitov
Journal:  Nature       Date:  2006-02-19       Impact factor: 49.962

Review 2.  Interleukin-12: biological properties and clinical application.

Authors:  Michele Del Vecchio; Emilio Bajetta; Stefania Canova; Michael T Lotze; Amy Wesa; Giorgio Parmiani; Andrea Anichini
Journal:  Clin Cancer Res       Date:  2007-08-15       Impact factor: 12.531

3.  Induction of higher-avidity human CTLs by vector-mediated enhanced costimulation of antigen-presenting cells.

Authors:  Sixun Yang; Kwong-Yok Tsang; Jeffrey Schlom
Journal:  Clin Cancer Res       Date:  2005-08-01       Impact factor: 12.531

4.  Human dendritic cell interactions with whole recombinant yeast: implications for HIV-1 vaccine development.

Authors:  Michelle A Barron; Naomi Blyveis; Samuel C Pan; Cara C Wilson
Journal:  J Clin Immunol       Date:  2006-05-13       Impact factor: 8.317

5.  Cross-presentation of HLA class I epitopes from influenza matrix protein produced in Saccharomyces cerevisiae.

Authors:  Andreas Wadle; Gerhard Held; Frank Neumann; Sascha Kleber; Beate Wuellner; Anne Marie Asemissen; Boris Kubuschok; Carmen Scheibenbogen; Tanja Breinig; Andreas Meyerhans; Christoph Renner
Journal:  Vaccine       Date:  2006-06-14       Impact factor: 3.641

6.  Whole recombinant yeast-based immunotherapy induces potent T cell responses targeting HCV NS3 and Core proteins.

Authors:  Aurelia A Haller; Georg M Lauer; Thomas H King; Charles Kemmler; Valerie Fiolkoski; Yingnian Lu; Don Bellgrau; Timothy C Rodell; David Apelian; Alex Franzusoff; Richard C Duke
Journal:  Vaccine       Date:  2006-11-10       Impact factor: 3.641

7.  Analyses of recombinant vaccinia and fowlpox vaccine vectors expressing transgenes for two human tumor antigens and three human costimulatory molecules.

Authors:  Kwong Y Tsang; Claudia Palena; Junko Yokokawa; Philip M Arlen; James L Gulley; Gail P Mazzara; Linda Gritz; Alicia Gómez Yafal; Sandra Ogueta; Patricia Greenhalgh; Kelledy Manson; Dennis Panicali; Jeffrey Schlom
Journal:  Clin Cancer Res       Date:  2005-02-15       Impact factor: 12.531

8.  Recombinant Saccharomyces cerevisiae (yeast-CEA) as a potent activator of murine dendritic cells.

Authors:  Michael B Bernstein; Mala Chakraborty; Elizabeth K Wansley; Zhimin Guo; Alex Franzusoff; Sven Mostböck; Helen Sabzevari; Jeffrey Schlom; James W Hodge
Journal:  Vaccine       Date:  2007-12-03       Impact factor: 3.641

9.  Candida albicans mannoprotein influences the biological function of dendritic cells.

Authors:  Donatella Pietrella; Giovanni Bistoni; Cristina Corbucci; Stefano Perito; Anna Vecchiarelli
Journal:  Cell Microbiol       Date:  2006-04       Impact factor: 3.715

10.  Early activation markers of human peripheral dendritic cells.

Authors:  Peter Hellman; Håkan Eriksson
Journal:  Hum Immunol       Date:  2007-02-20       Impact factor: 2.850

View more
  23 in total

1.  Maturation of human dendritic cells with Saccharomyces cerevisiae (yeast) reduces the number and function of regulatory T cells and enhances the ratio of antigen-specific effectors to regulatory T cells.

Authors:  Vittore Cereda; Matteo Vergati; Ngar-Yee Huen; Maria Giovanna di Bari; Caroline Jochems; Chiara Intrivici; James L Gulley; David Apelian; Jeffrey Schlom; Kwong Y Tsang
Journal:  Vaccine       Date:  2011-05-11       Impact factor: 3.641

2.  Identification and characterization of a cytotoxic T-lymphocyte agonist epitope of brachyury, a transcription factor involved in epithelial to mesenchymal transition and metastasis.

Authors:  Jo A Tucker; Caroline Jochems; Benjamin Boyerinas; Jonathan Fallon; John W Greiner; Claudia Palena; Timothy C Rodell; Jeffrey Schlom; Kwong-Yok Tsang
Journal:  Cancer Immunol Immunother       Date:  2014-09-04       Impact factor: 6.968

3.  Maturation and cytokine pattern of human dendritic cells in response to different yeasts.

Authors:  Silvia Boschi Bazan; Barbara Walch-Rückheim; Manfred J Schmitt; Frank Breinig
Journal:  Med Microbiol Immunol       Date:  2017-11-21       Impact factor: 3.402

Review 4.  Therapeutic cancer vaccines: current status and moving forward.

Authors:  Jeffrey Schlom
Journal:  J Natl Cancer Inst       Date:  2012-03-06       Impact factor: 13.506

Review 5.  Vaccines based on whole recombinant Saccharomyces cerevisiae cells.

Authors:  Andressa Ardiani; Jack P Higgins; James W Hodge
Journal:  FEMS Yeast Res       Date:  2010-12       Impact factor: 2.796

6.  Immune responses induced by heat killed Saccharomyces cerevisiae: a vaccine against fungal infection.

Authors:  Min Liu; Karl V Clemons; Marty Bigos; Izabela Medovarska; Elmer Brummer; David A Stevens
Journal:  Vaccine       Date:  2011-01-08       Impact factor: 3.641

Review 7.  Potential targets for pancreatic cancer immunotherapeutics.

Authors:  Lindzy F Dodson; William G Hawkins; Peter Goedegebuure
Journal:  Immunotherapy       Date:  2011-04       Impact factor: 4.196

8.  Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma.

Authors:  Marijo Bilusic; Christopher R Heery; Philip M Arlen; Myrna Rauckhorst; David Apelian; Kwong Y Tsang; Jo A Tucker; Caroline Jochems; Jeffrey Schlom; James L Gulley; Ravi A Madan
Journal:  Cancer Immunol Immunother       Date:  2013-12-07       Impact factor: 6.968

9.  Vaccine-mediated immunotherapy directed against a transcription factor driving the metastatic process.

Authors:  Andressa Ardiani; Sofia R Gameiro; Claudia Palena; Duane H Hamilton; Anna Kwilas; Thomas H King; Jeffrey Schlom; James W Hodge
Journal:  Cancer Res       Date:  2014-02-11       Impact factor: 12.701

10.  Yeast (Saccharomyces cerevisiae) Polarizes Both M-CSF- and GM-CSF-Differentiated Macrophages Toward an M1-Like Phenotype.

Authors:  Michelle Seif; Anja Philippi; Frank Breinig; Alexandra K Kiemer; Jessica Hoppstädter
Journal:  Inflammation       Date:  2016-10       Impact factor: 4.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.